title: Taming the TCR: antigen-specific immunotherapeutic agents for autoimmune diseases.
abstract: Current treatments for autoimmune diseases are typically non-specific anti-inflammatory agents that affect not only the autoreactive cells but also the parts of the immune system that are required to maintain health. There is a need for the development of antigen-specific therapeutic agents that can effectively prevent the autoimmune attack while leaving the rest of the immune system functioning as normal. The simplest way to achieve this is using the autoantigen itself as a tolerizing agent; however, there is some risk involved with administering a potentially pathogenic antigen. In this review, we focus instead on the development and use of modified T cell receptor (TCR) ligands, in which the peptide ligand is modified to change the response by the T cell from a disease inducing to a protective response, and still retain the antigen-specificity necessary to target the autoreactive T cells. We review the use of modified TCR ligands as therapeutic agents in animal models of autoimmunity and in human autoimmune disease, and finally consider how they need to be improved in order to use them effectively in patients with autoimmune disease.
authors.affiliation: a UQ Centre for Clinical Research , The University of Queensland , Brisbane , Queensland , Australia.
authors.forename: Evan L
authors.initials: EL
authors.lastname: Sauer
authors.affiliation: a UQ Centre for Clinical Research , The University of Queensland , Brisbane , Queensland , Australia.
authors.forename: Nancy C
authors.initials: NC
authors.lastname: Cloake
authors.affiliation: a UQ Centre for Clinical Research , The University of Queensland , Brisbane , Queensland , Australia.
authors.forename: Judith M
authors.initials: JM
authors.lastname: Greer
mesh_terms: D000818:Animals; D017951:Antigen Presentation / Q000276:immunology; D001324:Autoantigens / Q000276:immunology*; D001327:Autoimmune Diseases / Q000235:genetics / Q000276:immunology* / Q000378:metabolism* / Q000628:therapy; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D018984:Epitopes, T-Lymphocyte / Q000276:immunology*; D000949:Histocompatibility Antigens Class II / Q000737:chemistry / Q000276:immunology / Q000378:metabolism; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D008024:Ligands; D010455:Peptides / Q000737:chemistry / Q000276:immunology / Q000378:metabolism; D011485:Protein Binding / Q000276:immunology; D011948:Receptors, Antigen, T-Cell / Q000235:genetics / Q000378:metabolism*; D015398:Signal Transduction; D013601:T-Lymphocytes / Q000276:immunology / Q000378:metabolism; D016896:Treatment Outcome
chemical_list: D001324:Autoantigens; D018984:Epitopes, T-Lymphocyte; D000949:Histocompatibility Antigens Class II; D008024:Ligands; D010455:Peptides; D011948:Receptors, Antigen, T-Cell
keywords: CD4+ T cell; MHC; T cell receptor; antigen-specific; autoimmune disease